PMC:7228307 / 3200-3967 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"42","span":{"begin":734,"end":738},"obj":"Gene"},{"id":"43","span":{"begin":102,"end":120},"obj":"Disease"},{"id":"44","span":{"begin":163,"end":172},"obj":"Disease"},{"id":"45","span":{"begin":200,"end":207},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Gene:2213"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D001327"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D007239"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D004342"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":89,"end":98},"obj":"Body_part"},{"id":"T15","span":{"begin":176,"end":190},"obj":"Body_part"},{"id":"T16","span":{"begin":191,"end":196},"obj":"Body_part"},{"id":"T17","span":{"begin":192,"end":194},"obj":"Body_part"},{"id":"T18","span":{"begin":238,"end":242},"obj":"Body_part"},{"id":"T19","span":{"begin":401,"end":404},"obj":"Body_part"},{"id":"T20","span":{"begin":512,"end":518},"obj":"Body_part"},{"id":"T21","span":{"begin":703,"end":715},"obj":"Body_part"},{"id":"T22","span":{"begin":703,"end":707},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma62875"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma67653"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T9","span":{"begin":102,"end":120},"obj":"Disease"},{"id":"T10","span":{"begin":154,"end":172},"obj":"Disease"},{"id":"T11","span":{"begin":163,"end":172},"obj":"Disease"},{"id":"T12","span":{"begin":200,"end":207},"obj":"Disease"}],"attributes":[{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T33","span":{"begin":154,"end":159},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T34","span":{"begin":238,"end":242},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T35","span":{"begin":243,"end":253},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T36","span":{"begin":512,"end":518},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T37","span":{"begin":542,"end":552},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T38","span":{"begin":678,"end":680},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T39","span":{"begin":703,"end":707},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T40","span":{"begin":734,"end":736},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11","span":{"begin":229,"end":237},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T5","span":{"begin":176,"end":190},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T6","span":{"begin":192,"end":194},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A5","pred":"meddra_id","subj":"T5","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"},{"id":"A6","pred":"meddra_id","subj":"T6","obj":"http://purl.bioontology.org/ontology/MEDDRA/10021496"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T15","span":{"begin":113,"end":120},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T16","span":{"begin":154,"end":159},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T17","span":{"begin":163,"end":172},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T18","span":{"begin":238,"end":242},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T19","span":{"begin":703,"end":707},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"42","span":{"begin":734,"end":738},"obj":"Gene"},{"id":"43","span":{"begin":102,"end":120},"obj":"Disease"},{"id":"44","span":{"begin":163,"end":172},"obj":"Disease"},{"id":"45","span":{"begin":200,"end":207},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"pubann:denotes","subj":"43","obj":"MESH:D001327"},{"id":"A45","pred":"pubann:denotes","subj":"45","obj":"MESH:D004342"},{"id":"A42","pred":"pubann:denotes","subj":"42","obj":"Gene:2213"},{"id":"A44","pred":"pubann:denotes","subj":"44","obj":"MESH:D007239"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":374},"obj":"Sentence"},{"id":"T22","span":{"begin":375,"end":767},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T14","span":{"begin":89,"end":98},"obj":"Body_part"},{"id":"T15","span":{"begin":176,"end":190},"obj":"Body_part"},{"id":"T16","span":{"begin":191,"end":196},"obj":"Body_part"},{"id":"T17","span":{"begin":192,"end":194},"obj":"Body_part"},{"id":"T18","span":{"begin":238,"end":242},"obj":"Body_part"},{"id":"T19","span":{"begin":401,"end":404},"obj":"Body_part"},{"id":"T20","span":{"begin":512,"end":518},"obj":"Body_part"},{"id":"T21","span":{"begin":703,"end":715},"obj":"Body_part"},{"id":"T22","span":{"begin":703,"end":707},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma62875"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma67653"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T3","span":{"begin":238,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0001775"},{"id":"T4","span":{"begin":312,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0006915"},{"id":"T5","span":{"begin":325,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T6","span":{"begin":531,"end":552},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T7","span":{"begin":102,"end":120},"obj":"Disease"},{"id":"T8","span":{"begin":154,"end":172},"obj":"Disease"},{"id":"T9","span":{"begin":200,"end":207},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T2","span":{"begin":102,"end":120},"obj":"Phenotype"},{"id":"T3","span":{"begin":200,"end":207},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0012393"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002960"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T3","span":{"begin":238,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0001775"},{"id":"T4","span":{"begin":312,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0006915"},{"id":"T5","span":{"begin":325,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T6","span":{"begin":531,"end":552},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":238,"end":253},"obj":"http://purl.obolibrary.org/obo/GO_0001775"},{"id":"T4","span":{"begin":312,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0006915"},{"id":"T5","span":{"begin":325,"end":334},"obj":"http://purl.obolibrary.org/obo/GO_0097194"},{"id":"T6","span":{"begin":531,"end":552},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":374},"obj":"Sentence"},{"id":"T22","span":{"begin":375,"end":767},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":102,"end":120},"obj":"Phenotype"},{"id":"T3","span":{"begin":200,"end":207},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0012393"}],"text":"The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity. Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review."}